Key regions: United States, Spain, Europe, Thailand, Canada
The Pharmaceutical Cannabis market in Southern Europe is experiencing a significant growth trajectory driven by evolving customer preferences, market trends, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Customers in Southern Europe are increasingly turning to Pharmaceutical Cannabis products due to growing awareness of the potential health benefits associated with cannabis-derived pharmaceuticals. The shift towards natural and plant-based remedies is a key driver of this trend, as consumers seek alternative treatment options for various medical conditions.
Trends in the market: In Southern Europe, there is a noticeable trend towards the legalization and regulation of Pharmaceutical Cannabis products for medical use. Countries in the region are updating their legislation to allow for the production, distribution, and sale of pharmaceutical-grade cannabis products, creating new opportunities for companies operating in the market. Additionally, there is a growing focus on research and development within the Pharmaceutical Cannabis sector, leading to the introduction of innovative products and treatment options.
Local special circumstances: Southern Europe benefits from a favorable climate for cannabis cultivation, particularly in countries like Spain and Italy. This has led to the emergence of local cannabis producers who are able to supply high-quality raw materials for the pharmaceutical industry. Moreover, the region's strong tradition in pharmaceutical manufacturing and research provides a solid foundation for the development of Pharmaceutical Cannabis products.
Underlying macroeconomic factors: The Pharmaceutical Cannabis market in Southern Europe is also influenced by macroeconomic factors such as increasing healthcare expenditures and changing regulatory environments. As governments in the region look for cost-effective healthcare solutions, Pharmaceutical Cannabis is being considered as a viable option for addressing certain medical conditions. Furthermore, the economic impact of the COVID-19 pandemic has underscored the need for alternative healthcare treatments, further driving the demand for Pharmaceutical Cannabis products in the region.
Data coverage:
Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.Modeling approach / Market size:
Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.Additional Notes:
The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
